# Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

> **NCT05669599** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 592 (actual)

## Conditions studied

- Obesity
- Overweight
- Type 2 Diabetes Mellitus

## Interventions

- **BIOLOGICAL:** Maridebart Cafraglutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05669599
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-18
- **Primary completion:** 2024-10-08
- **Final completion:** 2025-12-16
- **Target enrollment:** 592 (ACTUAL)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05669599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05669599, "Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05669599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*